November 2026

ACR Convergence 2026

Tonmya® (Cyclobenzaprine HCl Sublingual Tablets; CBP SL): Efficacy and Safety Analyses of CBP SL 2.8 mg and 5.6 mg in Adults with Fibromyalgia

Tonmya® (TNX-102 SL; Cyclobenzaprine HCI Sublingual Tablets [CBP SL]) for the Treatment of Adults With Fibromyalgia: Number Needed to Treat, Numbers Needed to Harm and Likelihood to be Helped or Harmed: Results From a Pooled Analysis of Two Phase 3 Studies

October 2026

AMCP Nexus 2026

Characterizing Patients with Fibromyalgia: a U.S. Real-World Claims Analysis

Opioid Use in Patients with Fibromyalgia: a Retrospective Claims Analysis

October 2026

IASP 2026 World Congress on Pain

Cyclobenzaprine HCl Sublingual Reduces Fibromyalgia Impact on Physical Symptoms & Functional Ability

September 2026

PAINWeek 2026

Tonmya® (Cyclobenzaprine HCl Sublingual Tablets; CBP SL): Greater Absolute Pain Reduction with CBP SL 5.6 mg Compared to 2.8 mg in Adults with Fibromyalgia

Tonmya® (TNX-102 SL; Cyclobenzaprine HCI Sublingual Tablets [CBP SL]) for the Treatment of Adults With Fibromyalgia: Number Needed to Treat, Number Needed to Harm and Likelihood to be Helped or Harmed: Results from a Pooled Analysis of Two Phase 3 Studies

August 2026

2nd International Conference on Nociplastic Pain (ICON 2026)

Treatment With TNX-102 SL Produces Clinically Meaningful Improvements in Patient-Centered Outcomes in Fibromyalgia

Tonmya® (TNX-102 SL; Cyclobenzaprine HCI Sublingual Tablets [CBP SL]) for the Treatment of Adults With Fibromyalgia: Number Needed to Treat, Number Needed to Harm and Likelihood to be Helped or Harmed: Results from a Pooled Analysis of Two Phase 3 Studies

June 2026

Ninth JCA-AACR Special Joint Conference on Novel Therapies and Diagnostics in Upper Digestive and Head and Neck Cancers

TNX-1700, a First-in-Class CXCR4 Partial Agonist, Normalizes Myelopoiesis, and Enhances Anti-PD-1 Therapy in Gastric Cancer

June 2026

AANP 2026

Tonmya® (Cyclobenzaprine HCl Sublingual Tablets) Reduces Overall Impact of Fibromyalgia on Physical Symptoms and Functional Capacity

Tonmya® (TNX-102 SL; Cyclobenzaprine HCl Sublingual Tablets [CBP SL]) Improves Sleep Disturbance and Reduces Fatigue in Adults with Fibromyalgia

June 2026

EULAR 2026: Steady-state pharmacokinetic properties of a sublingual formulation of cyclobenzaprine (CBP) HCl: comparison to simulations of oral immediate-release CBP

May 2026

ISPOR 2026: Charactering Patients with Fibromyalgia: A U.S. Real-World Claims Analysis

May 2026

2nd Richard Slayman Clinical Xenotransplantation Workshop

TNX-1500: The History and Promise of α-CD154 Monoclonal Antibody Immunomodulation for Xenotransplantation